A Multicenter, Double Blinded, Randomized, Parallel Assignment Study to Demonstrate the Efficacy of DA9601
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This is a phase IV clinical study to evaluate the preventive effectiveness of
NSAID-Associated Gastroduodenal Injury. The study is consisted of multi-center, doubleblind,
active-controlled, stratified randomized, parallel group. A tablet of DA9601, Cytotec (200ug
of Misoprostol), Acrofen (100mg of Aceclofenac) will be assigned randomly to the subjects for
four weeks.